Anti-Fibrotic Effects Of A Novel Long-Acting Fgf21 Analogue Zalfermin

The potential clinical benefits of FGF21 analogues for the treatment of MASH has evolved significantly within the last years. However, despite clinical meaningful effect on MASH resolution and fibrosis the body weight loss in humans have been less impressive. Thus, a combination of an FGF21 analogue with a GLP-1 receptor agonist may add additional benefit to the treatment of MASH due to complimentary mode of action compared to stand alone therapies Overall design: RNA-sequencing data. UUO vehicle (n = 7), UUO zalfermin (n=8) and healthy vehicle (n = 4).